Sort
21,453 grants matching “tuberculosis”
CD1 IMMUNE RESPONSES AND VACCINES IN ANIMAL MODELS OF TB
$202,815Brigham And Women'S Hospital · R01 · FY2004 · AI
Rapid Diagnosis of Pediatric Tuberculosis
$202,775Harshini Mukundan · Triad National Security, Llc · R21 · FY2019 · AI
Mapping and modeling host-pathogen interactions in TB latency and reactivation
$202,768Maria Laura Gennaro · Univ Of Med/Dent Of Nj-Nj Medical School · R01 · FY2012 · HL
Role of LRRK2 in immunity in a nonhuman primate model of SIV
$202,754Krystal Vail · Tulane University Of Louisiana · K01 · FY2024 · OD
ANALYTICAL ASPECTS OF MOLECULAR EPIDEMIOLOGY
$202,658University Of California San Francisco · R01 · FY2000 · AI
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
$202,634Scott K Heysell · University Of Virginia · R01 · FY2021 · AI
"Role of IDO in tryptophan pathway during Mycobacterial tuberculosis infectionâ
$202,566Smriti Mehra · Louisiana State Univ A&M Col Baton Rouge · R21 · FY2017 · AI
Towards a new regimen to treat mycobacterial infection in cystic fibrosis patients
$202,500Gyanu Lamichhane · Johns Hopkins University · R21 · FY2016 · AI
Validation of RelA as a Target for Mycobacterium Tuberculosis Persisters
$202,500Petros C Karakousis · Johns Hopkins University · R21 · FY2015 · AI
A novel "shock and kill" strategy for eliminating Mtb persisters in the CD4 T-cell-deficient host
$202,500Petros C Karakousis · Johns Hopkins University · R21 · FY2017 · AI
Gut Microbiome and Pharmacokinetic Variability in Tuberculosis and Diabetes
$202,396Navaneeth Narayanan · Rutgers Biomedical And Health Sciences · K23 · FY2023 · AI
A Therapeutic Vaccine for HPV 16-Positive Head and Neck Cancer
$202,385Maura L Gillison · Ohio State University · R21 · FY2008 · CA
Understanding the mechanism of host responses to pathogen-derived DNA
$202,350Alexander Poltorak · Tufts University Boston · R21 · FY2020 · AI
Investigation of synergy between Rifampin and SQ109, a new anti-TB drug candidate
$202,331Venkata M Reddy · Sequella, Inc. · R21 · FY2008 · AI
Nanoformulation of Synergistic TLR Ligands to Enhance Amebiasis Vaccine Efficacy
$202,250Christopher B Fox · Access To Advanced Health Institute · R21 · FY2015 · AI
Screening for inhibitors of M. tuberculosis persistence-related lipid metabolism
$202,234Robert B Abramovitch · Michigan State University · R21 · FY2014 · AI
Gut Microbiome and Pharmacokinetic Variability in Tuberculosis and Diabetes
$202,217Navaneeth Narayanan · Rutgers Biomedical And Health Sciences · K23 · FY2024 · AI
Opportunities for multi-target drug discovery in tuberculosis
$202,145Lizbeth K. Hedstrom · Brandeis University · R21 · FY2019 · AI
TRANSMISSION DYNAMICS OF TB ALONG THE U.S.-MEXICO BORDER
$202,138University Of Texas Hlth Ctr At Tyler · R01 · FY2002 · AI
Clinical Core
$202,101C Robert Horsburgh · Rbhs-New Jersey Medical School · U19 · FY2019 · AI
Biostatistics and Data Management Resource Core
$202,016Debbie M Cheng · Boston Medical Center · P01 · FY2023 · AA
A rapid molecular approach to determine PZA susceptibility
$201,992Barry Neal Kreiswirth · Rbhs-New Jersey Medical School · R21 · FY2014 · AI
Vaccination strategies against pulmonary tuberculosis
$201,962Alistair John Ramsay · Lsu Health Sciences Center · R01 · FY2007 · AI
International Research in Thailand
$201,926Steven Holland · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
An Immunomics Approach To Explore Drug-Induced Resistance To Schistosomes
$201,925Rodrigo Correa-Oliveira · Foundation For Research Development · P50 · FY2015 · AI